Actively Recruiting
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
Led by Navy General Hospital, Beijing · Updated on 2020-09-09
100
Participants Needed
1
Research Sites
1056 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.
CONDITIONS
Official Title
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).
You will not qualify if you...
- Involved sites other than the brain, meninges, CSF, or the eyes.
- Age less than 18 years or greater than 75 years.
- Inadequate bone marrow capacity (neutrophils <1.5 �d710^9/L, platelets <100 �d710^9/L, hemoglobin <8 g/dL).
- Known cause of immunosuppression (e.g., HIV type I infection).
- Any previous malignancy.
- Creatinine clearance below 60 mL/min.
- Heart insufficiency (NYHA IIIB or IV).
- Uncontrolled infection.
- Noncompensated active pulmonary or liver disease.
- Previously treated for PCNSL, except by corticosteroids.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Navy General Hospital
Beijing, Beijing Municipality, China, 100048
Actively Recruiting
Research Team
L
Liren Qian, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here